Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Burhenne

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Journal of Medical Screening|December 29, 2000
Ten years of breast screening in the Screening Mammography Program of British Columbia, 1988-97I A Olivotto, L Kan, Y d'Yachkova, et al.
The Pharmacogenomics Journal|October 24, 2012
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patientsA Habtewold, W Amogne, E Makonnen, et al.
American Journal of Surgery|May 1, 1988
Human amnion as a bioprosthesis for bile duct reconstruction in the pigC H Scudamore, C D Becker, J S Fache, et al.
British Journal of Clinical Pharmacology|April 5, 2018
Higher chlorzoxazone clearance in obese children compared with nonobese peersC Gade, K Dalhoff, T S Petersen, et al.
The Pharmacogenomics Journal|August 25, 2011
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort studyG Yimer, W Amogne, A Habtewold, et al.
AJR. American Journal of Roentgenology|November 1, 1982
Evaluation of 12 colon-cleansing regimens with single-contrast barium enemaA J Present, B Jansson, H J Burhenne, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavirF Josephson, A Allqvist, M Janabi, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patientsE Ngaimisi, S Mugusi, O M Minzi, et al.
Clinical Pharmacology and Therapeutics|August 5, 2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosisE Ngaimisi, S Mugusi, O Minzi, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2014
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatmentE Ngaimisi, O Minzi, S Mugusi, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Journal of Medical Screening|December 29, 2000
Ten years of breast screening in the Screening Mammography Program of British Columbia, 1988-97I A Olivotto, L Kan, Y d'Yachkova, et al.
The Pharmacogenomics Journal|October 24, 2012
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patientsA Habtewold, W Amogne, E Makonnen, et al.
American Journal of Surgery|May 1, 1988
Human amnion as a bioprosthesis for bile duct reconstruction in the pigC H Scudamore, C D Becker, J S Fache, et al.
British Journal of Clinical Pharmacology|April 5, 2018
Higher chlorzoxazone clearance in obese children compared with nonobese peersC Gade, K Dalhoff, T S Petersen, et al.
The Pharmacogenomics Journal|August 25, 2011
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort studyG Yimer, W Amogne, A Habtewold, et al.
AJR. American Journal of Roentgenology|November 1, 1982
Evaluation of 12 colon-cleansing regimens with single-contrast barium enemaA J Present, B Jansson, H J Burhenne, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavirF Josephson, A Allqvist, M Janabi, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patientsE Ngaimisi, S Mugusi, O M Minzi, et al.
Clinical Pharmacology and Therapeutics|August 5, 2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosisE Ngaimisi, S Mugusi, O Minzi, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2014
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatmentE Ngaimisi, O Minzi, S Mugusi, et al.
Pageof 13